Table 5 Audit recommendations

We propose the following audit measures focusing on those guidelines supported by robust randomised evidence:

1

The proportion of people with each grade 1 Recommendation for use prescribed an SGLT- 2 inhibitor (with exploration of reasons for non-use to direct quality improvement projects)

2

The proportion of people prescribed an SGLT-2 inhibitor not on concomitant RAS blockade

3

The proportion of people with CKD on SGLT-2 inhibitors with evidence of provision of sick day guidance

4

The proportion of people with CKD in whom SGLT-2 inhibitors were withheld during acute illness, and the proportion appropriately re-initiated on recovery

5

The proportion of people on Insulin/SUs with HbA1c < 58 mmol/mol and eGFR > 45 mL/min/1.73m², whose therapy was appropriately reduced when initiating SGLT-2 inhibitors